Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SchistoShield Vaccine in Healthy Adults in Burkina Faso and Madagascar
NCT05762393Phase 1Completed
- Sponsor
- International Vaccine Institute
- Start
- Nov 2023
- Primary completion
- May 2025
- Modality
- Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
- Countries
- 2
01
Overview
Phase 1, randomised, double-blind trial of SchistoShield in schistosomiasis (3 cohorts), sponsored by International Vaccine Institute. Primary endpoints: Proportion of Participants With Any Serious Adverse Events (SAEs)/ Adverse Events of Special Interest (AESI) at Day 224, Proportion of Participants With Immediate Adverse Events (Reactogenicity Events) at Day 56 and 3 more. Started Nov 2023; status: completed.
02
Drugs
SchistoShield
03
Conditions
schistosomiasis
Beyond the preview
Go deeper on NCT05762393.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05762393.